SLC5A2 and diabetes mellitus: Many studies showed the possibility that SGLT2 inhibitors improve or restore autophagy in diabetic disease models;[32–35] thus, autophagy is considered an underlying mechanism for cardioprotective and renoprotective effects in patients with diabetes mellitus using SGLT2 inhibitors [24, 25].